Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Sangamo Therapeutics
SGMO
Sangamo Therapeutics
Rising Funding Needs Will Threaten Fabry Trials And Inspire Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.50
64.0% undervalued
intrinsic discount
16 Aug
US$0.54
1Y
-34.0%
7D
-3.7%
Loading
1Y
-34.0%
7D
-3.7%
Author's Valuation
US$1.5
64.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.5
64.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-250m
218m
2014
2017
2020
2023
2025
2026
2028
Revenue US$43.0m
Earnings US$7.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
35.30%
Biotech revenue growth rate
11.84%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.87%
Calculation
US$6.98m
Earnings '28
x
173.74x
PE Ratio '28
=
US$1.21b
Market Cap '28
US$1.21b
Market Cap '28
/
662.86m
No. shares '28
=
US$1.83
Share Price '28
US$1.83
Share Price '28
Discounted to 2025 @ 6.86% p.a.
=
US$1.50
Fair Value '25
